Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma
OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial
Read morePress Releases
Opna Bio Announces Orphan Drug Designation Granted to OPN-2853 (Zavabresib) for the Treatment of Myelofibrosis
SOUTH SAN FRANCISCO, CA – January 21, 2026 – Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and […]
Read moreOpna Bio Showcases Multi-Functional Degraders with Potent Anti-Myeloma Activity and Encouraging Spleen Reductions in Patients with Myelofibrosis Treated with OPN-2853 and Ruxolitinib
Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH)
Read moreOpna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program and Updated Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Advanced Myelofibrosis
Phase 1 Clinical Trial with OPN-6602 in Multiple Myeloma Actively Enrolling Patients
Read moreOpna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma
OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma
Read moreOpna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis
Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies
Read moreOpna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor
Appoints Axel Bolte, MBA, MSc to Board Director and Stephanie Oestreich, PhD, MPA to Board Observer
Read moreOpna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting
OPN-6602 Expected to Begin Phase 1 Clinical Study in Multiple Myeloma in Summer 2024
Read more
